The Culprit Behind HBV-Infected Hepatocytes: NTCP
Drug Design, Development and Therapy · 2024
DOI: 10.2147/dddt.s480151 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2024. Verfasst von Shenghao Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China. Hauptthemen laut MEDLINE: Organic Anion Transporters, Sodium-Dependent, Symporters, Hepatocytes, Hepatitis B virus. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Hepatitis B virus (HBV) is a globally prevalent human DNA virus responsible for over 250 million cases of chronic liver infections, leading to conditions such as liver inflammation, cirrhosis and hepatocellular carcinoma (HCC). Sodium taurocholate co-transporting polypeptide (NTCP) is a transmembrane protein highly expressed in human hepatocytes and functions as a bile acid (BA) transporter. NTCP has been identified as the receptor that HBV and its satellite virus, hepatitis delta virus (HDV), use to enter hepatocytes. HBV entry into hepatocytes is tightly regulated by various signaling pathways, and NTCP plays an important role as the initial stage of HBV infection. NTCP acts as an initiation signal, causing metabolic changes in hepatocytes and facilitating the entry of HBV into hepatocytes. Thus, a comprehensive understanding of NTCP's role is crucial. In this review, we will examine the regulatory mechanisms governing HBV pre-S1 binding to liver membrane NTCP, the role of NTCP in HBV internalization, and the transcriptional and translational regulation of NTCP expression. Additionally, we will discuss clinical drugs targeting NTCP, including combination therapies involving NTCP inhibitors, and consider the safety of NTCP as a therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China.
- Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, People's Republic of China.
- Department of Infectious Diseases, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu Province, People's Republic of China.
ORCID-Profile: Junli Zhang, Fei Yu, Fanghang Ye
Zitieren
APA
Li, S., Hao, L., Deng, J., Zhang, J., Yu, F., Ye, F., Li, N., & Hu, X. (2024). The Culprit Behind HBV-Infected Hepatocytes: NTCP. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s480151
Vancouver
Li S, Hao L, Deng J, Zhang J, Yu F, Ye F, et al. The Culprit Behind HBV-Infected Hepatocytes: NTCP. Drug Design, Development and Therapy. 2024. doi:10.2147/dddt.s480151
BibTeX
@article{Li2024,
author = {Li, Shenghao and Hao, Liyuan and Deng, Jiali and Zhang, Junli and Yu, Fei and Ye, Fanghang and Li, Na and Hu, Xiaoyu},
title = {The Culprit Behind HBV-Infected Hepatocytes: NTCP},
journal = {Drug Design, Development and Therapy},
year = {2024},
doi = {10.2147/dddt.s480151}
}
EUVIMED